Heparin-induced thrombocytopenia pathophysiology: Difference between revisions
Rim Halaby (talk | contribs) m Changed protection level for "Heparin-induced thrombocytopenia pathophysiology" ([Edit=Allow only autoconfirmed users] (expires 14:28, 7 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 14:28, 7 January 2014 (UTC))) |
mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Heparin-induced thrombocytopenia}} | {{Heparin-induced thrombocytopenia}} | ||
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] | {{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com] | ||
==Overview== | ==Overview== | ||
[[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. It is caused by antibodies to complexes between [[heparin]] and [[platelet factor 4]] (PF4). These antibody complexes stimulates the procoagulant pathways due to activation of [[platelet]] and [[endothelium]]. | [[Heparin-induced thrombocytopenia]] is diagnosed when the [[platelet]] count falls by > 50% typically after 5-10 days of [[heparin]] therapy. It is caused by antibodies to complexes between [[heparin]] and [[platelet factor 4]] (PF4). These antibody complexes stimulates the procoagulant pathways due to activation of [[platelet]] and [[endothelium]]. | ||
| Line 14: | Line 16: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WS}} | |||
{{WH}} | |||
Revision as of 19:40, 17 June 2016
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia pathophysiology |
|
Heparin-induced thrombocytopenia pathophysiology in the news |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. It is caused by antibodies to complexes between heparin and platelet factor 4 (PF4). These antibody complexes stimulates the procoagulant pathways due to activation of platelet and endothelium.
Pathophysiology
- It is caused by antibodies to complexes between heparin and platelet factor 4 (PF4).
- More than 90% patients have these anti–PF4-heparin antibodies in their plasma.
- These antibodies bind to the platelet's surface and induce their activation by cross-linking Fc IIA receptors and bind to the surface of the endothelium, inducing procoagulant activity.
- Platelets activated with these antibodies, increase their release of platelet factor 4 (PF4). Thus, a viscous cycle continues.